|
Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active RheumatoidArthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated. It was developed by the biotech company AbbVie. Common side effects include upper respiratory tract infections (common cold, sinus infections), Nausea, Cough, and Fever.[from Wikipedia]
|